SPECIAL APPROACHES TO BREAST CANCER HORMONAL THERAPY OF YOUNG PATIENTS

D N Kravchenko; A A Parokonnaya; M I Nechushkin; D E Avtomonov

doi:10.17816/clinpract7215-20

Journal of Clinical Practice ›› 2016, Vol. 7 ›› Issue (2) : 15 -20. DOI: 10.17816/clinpract7215-20

Articles

research-article

SPECIAL APPROACHES TO BREAST CANCER HORMONAL THERAPY OF YOUNG PATIENTS

Author information +

History +

PDF

Abstract

Breast cancer is the most prevalent female malignancy. When diagnosed at young age (up to 40 years), negative clinical, morphological and prognostic features are noted. A non-randomized retrospective trial (n=500) was performed to evaluate different scenarios of breast cancer hormone therapy in young patients. Ovarian suppression in young patients is shown to statistically improve prognosis. Disease-free survival rate values are observed to decrease in patients without ovarian suppression in comparison with any type of ovarian suppression, especially at a remote follow-up (after 60 months). Menstrual function resumption and no amenorrhea after chemotherapy significantly decrease disease-free survival rate values in young patients.

Keywords

breast cancer / hormonal therapy / young / survival / chemotherapy / hormone therapy

Cite this article

Download citation ▾

D N Kravchenko, A A Parokonnaya, M I Nechushkin, D E Avtomonov. SPECIAL APPROACHES TO BREAST CANCER HORMONAL THERAPY OF YOUNG PATIENTS. Journal of Clinical Practice, 2016, 7(2): 15-20 DOI:10.17816/clinpract7215-20

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin 2011;61:409-18.

[2]	Francis P. Optimal adjuvant therapy for very young breast cancer patients. Breast. 2011 Aug; 20(4): 297-302.

[3]	Torino F., Barnabei A., de Vecchis L., et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer Crit Rev Oncol Hematol. 2014 Jan;89(1):27-42.

[4]	Taylor C.W., Green S., Dalton W.S. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive breast cancer: an intergroup study. J Clin Oncol. 1998 Mar;16(3):994-9.

[5]	Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol. 2012 Apr; 6(2):222-36.

[6]

Wu S, Li Q, Zhu Y, Sun J, Li F, et al. Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study. Cancer biotherapy and pharmaceuticals. Cancer Biother Radiopharm. 2013 Dec; 28 (10): 697-702.

[7]	Ignatiadis M, Buyse M, Sotiriou C. St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists. Ann Oncol. 2015 Aug; 26 (8):1519-20.

[8]	Moore H., Unger J., Kelly A., et al. Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy NEJM 2015; 372(10): 923-32.

[9]	Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015 Dec; 26 (12): 2408-19.